Invasive Aspergillosis in a Patient with Stage III (or 3a or 3b) Non-Small-Cell Lung Cancer Treated with Durvalumab
Joint Authors
Guevara, Elizabeth
Gupta, Ashish
Tun, Aung
Ticona, Katy
Baqui, Aam
Source
Case Reports in Oncological Medicine
Issue
Vol. 2019, Issue 2019 (31 Dec. 2019), pp.1-4, 4 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2019-08-27
Country of Publication
Egypt
No. of Pages
4
Main Subjects
Abstract EN
Durvalumab is a therapeutic monoclonal antibody that blocks the checkpoint inhibitor, programmed death ligand 1 (PD-L1), resulting in T-cell activation and an antitumor response.
Durvalumab is approved for patients with unresectable stage III non-small-cell lung cancer (NSCLC) which has not progressed following platinum-based chemoradiotherapy.
A 63-year-old man presented to the emergency department with a 15-day history of increasing shortness of breath.
Several months previously, he had been diagnosed with a poorly differentiated stage IIIB NSCLC.
He had completed six cycles of chemotherapy with paclitaxel and carboplatin and four cycles of immunotherapy with durvalumab 13 days before his emergency hospital admission.
Computed tomography (CT) imaging showed a large left-sided loculated hydropneumothorax suggestive of empyema, patchy opacification of the left lung, and a left upper lobe lung mass.
Histology of the cell block from the pleural fluid and decorticated lung tissue showed hyphae suggestive of invasive Aspergillus fumigatus.
Treatment with voriconazole resulted in clinical improvement.
To our knowledge, this is the first reported case of pleural aspergillosis in a patient treated with durvalumab.
However, the increasing use of immune checkpoint inhibitors in oncology requires increased awareness by clinicians of immune-related adverse events (irAEs) due to opportunistic infection.
American Psychological Association (APA)
Gupta, Ashish& Tun, Aung& Ticona, Katy& Baqui, Aam& Guevara, Elizabeth. 2019. Invasive Aspergillosis in a Patient with Stage III (or 3a or 3b) Non-Small-Cell Lung Cancer Treated with Durvalumab. Case Reports in Oncological Medicine،Vol. 2019, no. 2019, pp.1-4.
https://search.emarefa.net/detail/BIM-1141866
Modern Language Association (MLA)
Gupta, Ashish…[et al.]. Invasive Aspergillosis in a Patient with Stage III (or 3a or 3b) Non-Small-Cell Lung Cancer Treated with Durvalumab. Case Reports in Oncological Medicine No. 2019 (2019), pp.1-4.
https://search.emarefa.net/detail/BIM-1141866
American Medical Association (AMA)
Gupta, Ashish& Tun, Aung& Ticona, Katy& Baqui, Aam& Guevara, Elizabeth. Invasive Aspergillosis in a Patient with Stage III (or 3a or 3b) Non-Small-Cell Lung Cancer Treated with Durvalumab. Case Reports in Oncological Medicine. 2019. Vol. 2019, no. 2019, pp.1-4.
https://search.emarefa.net/detail/BIM-1141866
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1141866